Thread by @T_Fiolet

❌ Our meta-analysis including 15,081 patients (16 studies) does NOT support the use of hydroxychloroquine with or without azithromycin to reduce COVID-19 mortality in hospitalized patients

➡️ medrxiv.org/content/10.110…

#Hydroxychloroquine #COVID19 #Hydroxychloroquineworks

Hydroxychloroquine was not significantly associated with mortality risk (RR=0.82 [0.62-1.07], I²=82, Pheterogeneity<0.01, n=15)) within hospitalized patients, nor in association with azithromycin (RR=1.33 (95% CI: 0.92-1.92, n=6))

nor in the numerous subgroup analysis by study design, median age population, published studies (vs unpublished articles), level of bias risk

Stratified analysis by continents, we found a significant decreased risk of mortality associated with HCQ alone but not with azithromycin among European (RR= 0.62 [0.41-0.93], n=7)) and Asian studies (RR=0.36 [0.18-0.73], n=1)), with heterogeneity detected across continent

Five of these European studies have a SERIOUS or CRITICAL risk of bias. Additionally, this significant relationship could be explained by a high risk of confusion bias since these articles did not reported adjusted effect size.

It raises the question of the hydroxychloroquine use outside of clinical trial. Additional results from larger randomised controlled trials are needed

I would like to thank for this fruitful collaboration @Damkyan_Omega @AnthonyGuihur @Nibor_Tolum @Mht_Saleh_yahya

Please do not hesitate to share your feedbacks and to give us your comments 😄

En français ⤵️

https://twitter.com/T_Fiolet/status/1274021304740519936?s=20

Poke @ABsteward